ESTABLISHING THE DOSE-DEPENDENT DAILY VARIATIONS OF A LOW MOLECULAR WEIGHT HEPARIN (FRAXIPARINE®) THROUGH A POPULATION APPROACH ANALYSIS IN THE RAT

REFERENCES

• Amar J, Caranobe C, Sie P, et al. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities, an experimental study in two models of thrombosis. Br J Haematol. 1990; 76: 94–100
   PubMed Web of Science ®Google Scholar
• Andersson L O, Barrowcliffe T W, Holmer E, et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531–41
   PubMed Web of Science ®Google Scholar
• Andriuoli G, Mastacchi R, Barbanti M, et al. Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats. Haemostasis 1985; 15: 324–30
   PubMedGoogle Scholar
• Bara L, Samama M M. Pharmacokinetics of low molecular weight heparin. Acta Clin Scand 1988; 543: 65–72
   Google Scholar
• Beal S L. Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab Rev 1984; 15: 173–193
   PubMed Web of Science ®Google Scholar
• Beal S L, Sheiner L B. Conditional estimation methods. NONMEM users guide. VII, University of California, San Francisco, California 1992
   Google Scholar
• Bianchini P, Bergonzini G L, Parma B, et al. Relationship between plasma antifactor Xa activity and the antithrombotic activity of heparins of different molecular mass. Haemostasis 1995; 25: 288–98
   PubMedGoogle Scholar
• Cohen M, Simons D J, Joist J H. Diurnal hemostatic changes in the rat. Thromb Res 1978; 12: 965–71
   PubMed Web of Science ®Google Scholar
• Damus P S, Hicks M, Rosenberg R D. Anticoagulant effect of heparin. Nature 1973; 246: 355–57
   PubMed Web of Science ®Google Scholar
• Decousus H, Croze M, Levi F, et al. Circadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med J 1985; 290: 341–44
   PubMed Web of Science ®Google Scholar
• Decousus H, Scully M F, Reynaud J. Circadian changes in anticoagulant effect of heparin given by subcutaneous bolus. Thromb Haemost 1987; 58: 1376
   Web of Science ®Google Scholar
• Dejana E, Quintana A, Callioni A, et al. Bleeding time in laboratory animals 2—a comparison of different assay conditions in rats. Thromb Res 1979; 15: 191–97
   PubMed Web of Science ®Google Scholar
• Dejana E, Villa S, De Gaetano G. Bleeding time in rats, a comparison of different experimental conditions. Thromb Haemost 1982; 48(1)108–11
   PubMed Web of Science ®Google Scholar
• Estes J W. The fate of heparin in the body. Curr Ther Res Clin E 1975; 18(1)45–57
   PubMed Web of Science ®Google Scholar
• Gries J M, Benowitz N, Verotta D. Chronopharmacokinetics of nicotine. Clin Pharmacol Ther 1996; 60: 385–95
   PubMed Web of Science ®Google Scholar
• Lane D A, MacGregor I R, Michalski R, et al. Anticoagulant activities of four unfractionated and fractionated heparin. Thromb Res 1978; 12: 257–71
   PubMed Web of Science ®Google Scholar
• Mandema J W, Verotta D, Sheiner L B. Building population pharmacokinetic-pharmacodynamic models. 1 Models for covariate effects. J Pharmacokinet Biopharm 1992; 20(5)511–28
   PubMedGoogle Scholar
• Migaud-Fressart M, Roisin J P, Masset N. Evaluation of new routine APTT (liquid form). Thromb Haemost 1993; 69(6-abst)2075–1123
   Web of Science ®Google Scholar
• Mismetti P, Perpoint B, Laporte-Simitsidis S, et al. Chronopharmacologie d'une héparine fractionnée (nadroparine) administrée par voie sous-cutanée à dose prophylactique chez le volontaire sain. Therapie 1992; 47: 557–60
   PubMedGoogle Scholar
• Mismetti P, Reynaud J, Tardy-Poncet B, et al. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in 10 healthy volunteers. Thromb Haemost 1995; 74(2)660–66
   PubMed Web of Science ®Google Scholar
• Rowland M, Benet L Z, Graham G G. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1973; 1(2)123–36
   PubMedGoogle Scholar
• Scheving L E, Pauly J E. Daily rhythmic variations in blood coagulation times in rats. Anat Rec 1967; 157: 657–66
   PubMedGoogle Scholar
• Sheiner L B, Ludden T M. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992; 32: 185–209
   PubMed Web of Science ®Google Scholar
• Sheiner L B, Rosenberg B, Marathe V V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445–79
   PubMedGoogle Scholar
• Soulban G, Labrecque G. Biological rhythms of blood coagulation and the effect of warfarin in rats. Annu Rev Chronobiol 1988; 5: 465–68
   Google Scholar
• Soulban G, Labrecque G, Barbeau G. Time dependent variations in the coagulation factors II, VII, IX and X in young and elderly volunteers. Chronobiol Int 1995; 12(3)206–13
   Web of Science ®Google Scholar
• Teien A M, Lie M, Abildgaard U. Assay of heparin plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 13: 285
   Google Scholar